InsidersTradesSigma
Track the TScan Therapeutics, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, TScan Therapeutics, Inc. has published 26 reports. Market capitalisation: €59.8m. The latest transaction was reported on 23 December 2025 (Acquisition). Among the most active insiders: Lynx1 Capital Management LP. The full history is accessible without an account.
26
Insider Decl.
n/a
Thresholds
€4m
21 ops.
Buy Volume
€23,513
1 ops.
Sell Volume
51Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 December 2025
Declarations26 total
80,069 shares@ US$0.89893.7% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-005396:0
Canonical exit: 19 Mar 2026 (T+90)
1,388,794 shares@ US$1.2092.6% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-002511:0
Canonical exit: 17 Aug 2025 (T+90)
31,800 shares@ US$3.00725.7% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-24-006934:0
Canonical exit: 12 Mar 2025 (T+90)
947 shares@ US$4.34420.2% of flowCommon stock, $0.0001 par value per shareSEC:0000902664-24-006718:0
Canonical exit: 13 Feb 2025 (T+90)
5,000 shares@ US$5.2932.7% of flowVoting Common StockSEC:0000950170-24-109133:0
Canonical exit: 22 Dec 2024 (T+90)
5,000 shares@ US$5.6935.2% of flowVoting Common StockSEC:0000950170-24-101166:0
Canonical exit: 21 Nov 2024 (T+90)
54,895 shares@ US$4.8579.9% of flowVoting Common StockSEC:0000950170-24-101161:0
28,830 shares@ US$4.886658.3% of flowVoting Common StockSEC:0000950170-23-072291:0
Canonical exit: 17 Mar 2024 (T+90)
5,000 shares@ US$5.0832.1% of flowVoting Common StockSEC:0000950170-23-071208:0
Canonical exit: 13 Mar 2024 (T+90)
37,880 shares@ US$2.628441.7% of flowVoting Common StockSEC:0000899243-23-014618:0
Canonical exit: 31 Aug 2023 (T+90)
10,000 shares@ US$2.51481.5% of flowCommon stock, $0.0001 par value per share Common StockSEC:0000902664-23-003407:0
2,842 shares@ US$1.50471.9% of flowVoting Common StockSEC:0000899243-22-039506:0
Canonical exit: 27 Mar 2023 (T+90)
15,000 shares@ US$3.62260.079% mcap13.5% of flowVoting Common StockSEC:0000899243-22-019018:0
Canonical exit: 16 Aug 2022 (T+90)
40,800 shares@ US$1.700.10% mcap2.4% of flowCommon StockSEC:0001209191-22-028579:0
Canonical exit: 8 Aug 2022 (T+90)
15,000 shares@ US$3.39880.071% mcap22.0% of flowVoting Common StockSEC:0000899243-22-012476:0
Canonical exit: 22 Jun 2022 (T+90)
48,670 shares@ US$1.970.13% mcap22.1% of flowVoting Common StockSEC:0000899243-21-049764:0
4,716 shares@ US$7.475711.1% of flowVoting Common StockSEC:0000899243-21-037802:0
Canonical exit: 22 Dec 2021 (T+90)
4,943 shares@ US$6.2197100.0% of flowVoting Common StockSEC:0000899243-21-037147:0
Canonical exit: 19 Dec 2021 (T+90)
5,000 shares@ US$6.31720.4% of flowVoting Common StockSEC:0000899243-21-037149:0
Canonical exit: 20 Dec 2021 (T+90)
5,885 shares@ US$8.483531.9% of flowVoting Common StockSEC:0000899243-21-035684:0
Canonical exit: 8 Dec 2021 (T+90)
11,000 shares@ US$8.733337.3% of flowVoting Common StockSEC:0000899243-21-035442:0
Canonical exit: 7 Dec 2021 (T+90)
2,500 shares@ US$9.0832100.0% of flowVoting Common StockSEC:0000899243-21-034610:0
Canonical exit: 25 Nov 2021 (T+90)
1,145,505 sharesVoting Common StockSEC:0000899243-21-029479:0
33,259 sharesVoting Common StockSEC:0000899243-21-029440:0
104,698 shares@ US$15.0095.3% of flowCommon StockSEC:0001638599-21-000606:0
Canonical exit: 18 Oct 2021 (T+90)
25 of 26 declarations
关于 TScan Therapeutics, Inc.
TScan Therapeutics, Inc. 是一家美国生物技术公司，在美国纳斯达克市场上市。该公司旨在通过T细胞受体工程化T细胞（TCR-T）疗法，寻求更精准的癌症免疫疗法。其运营总部位于马萨诸塞州沃尔瑟姆，这是波士顿地区一个主要的生物技术集群。对于投资者而言，TScan最好被视为一家临床阶段的肿瘤平台公司：它具有重要的科学选择权，但也承担着早期到中期细胞疗法开发商典型的执行、资金和监管风险。 TScan的核心业务围绕一个专有发现平台，该平台能够识别在特定HLA类型背景下识别肿瘤相关抗原的天然T细胞受体。该平台支撑着涵盖血液恶性肿瘤和实体瘤的管线。在血液癌症方面，该公司正在推进供体来源的同种异体TCR-T候选药物，旨在减少残余疾病并预防造血细胞移植后的复发。在实体瘤方面，TScan正在构建一个更广泛的ImmunoBank和一个T-Plex框架下的多重治疗概念，旨在根据患者的肿瘤靶点和HLA谱同时施用多达三种TCR-T候选产品。 一个显著的竞争优势是TScan在沃尔瑟姆的内部GMP生产能力。在一个制造复杂性可能减缓开发并增加成本的领域，拥有部分生产基础设施具有战略重要性。它支持跨项目的更快迭代，并可能帮助公司比完全依赖外部制造合作伙伴的同行更有效地扩大临床供应。该公司还强调其非病毒工程方法和HLA覆盖范围的扩展，这两者都旨在扩大患者资格并增强其管线的临床相关性。 从市场定位来看，TScan在细胞疗法和肿瘤学领域竞争激烈，差异化取决于临床数据、转化生物学和可制造性。该公司仍处于商业化前阶段，因此尚未获得产品销售的支持；其近期价值驱动因素是临床里程碑、监管备案和现金储备。在2025年和2026年初的最新公开更新中，TScan强调了其血液项目战略优先化、FDA批准TSC-102-A01和TSC-102-A03的IND申请，以及更新的临床数据演示。该公司还表示，其现金资源预计将为运营提供资金至2027年下半年，这对于一家开发阶段的生物技术公司来说是一个重要的基准。总的来说，TScan结合了差异化的科学平台和大量的二元事件风险敞口，使其成为公共股权投资者的高风险、高回报标的。
